Taking people in GreecePhase 1
Tests budoprutug in adults with systemic lupus erythematosus
Tests budoprutug, an experimental drug, in adults with lupus affecting the whole body.
Plain-language title generated from the registry record
Registry title: A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus
Key facts
- Where
- Athens and Thessaloniki, GreeceSee the 3 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Systemic Lupus Erythematosus to study how well and how safe budoprutug (TNT119) is.
- Age
- 18 years or older
- Sex
- All sexes can join
Read by machine on 9 November 2026.
Where in Greece
- Laiko General Hospital of AthensAthens, GreeceTaking people
- Geniko Nosokomeio Thessalonikis George PapanikolaouThessaloniki, GreeceTaking people
- Ippokratio General Hospital of ThessalonikiThessaloniki, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Climb Bio Inc.
- Trial code
- EU 2024-520385-57-01
- Record updated
- 30 June 2026